Zim Laboratories Ltd Stock Price Today (NSE: ZIMLAB)
Fundamental Score
Zim Laboratories Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Zim Laboratories Ltd share price today is ₹71.16, up +0.00% on NSE/BSE as of 20 February 2026. Zim Laboratories Ltd (ZIMLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹356.59 (Cr). The 52-week high for ZIMLAB share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 54.11x, ZIMLAB is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 4.96% and a debt-to-equity ratio of 0.48.
Zim Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Zim Laboratories Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Zim Laboratories Share Price Analysis: A Growth Strategist Perspective
The pharmaceutical industry, often considered recession-proof, is currently witnessing a significant shift towards specialized drug delivery systems and patient-centric formulations. This trend creates opportunities for companies focusing on innovation and niche markets. This financial analysis examines the current standing of Zim Laboratories share price in light of its financial metrics and peer performance, as part of a larger 80-parameter fundamental audit verified by Sweta Mishra.
Currently, Zim Laboratories Ltd is trading at ₹71.68 with a Price-to-Earnings (PE) ratio of 54.11. This valuation suggests investors have high expectations for future earnings growth. However, comparing this PE to sector peers offers a crucial perspective. Competitors such as Mankind Pharma Ltd, Smruthi Organics Ltd, and Balaxi Pharmaceuticals Ltd operate within similar market dynamics, and their respective valuations and performance offer context for Zim Laboratories. Specifically, considering
Mankind Pharma Ltd, we see a market perception, arguably driven by management quality, that often supports premium valuations, something Zim Laboratories currently needs to address.A critical factor impacting the long-term viability and "moat" of Zim Laboratories is its Return on Capital Employed (ROCE) of 8.16%. ROCE indicates how efficiently a company is generating profits from its capital. While positive, 8.16% suggests there is room for improvement. A higher ROCE signifies a stronger competitive advantage, implying the company can generate more profit per rupee of capital employed compared to its peers. This relatively lower ROCE indicates that Zim Laboratories needs to optimize capital allocation and improve operational efficiencies to enhance its profitability and strengthen its market position. Strategies for improvement could include focusing on higher-margin product segments, improving supply chain management, and enhancing R&D efforts to develop innovative and differentiated products.
This analysis offers an observational perspective on Zim Laboratories' current financial standing. Further investigation into specific product pipelines, debt levels, and future growth strategies is necessary for a more comprehensive assessment. The relationship between the current Zim Laboratories share price and its long-term potential hinges on the company's ability to effectively execute its growth strategy and improve its underlying financial performance, especially its ROCE.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Zim Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ZIMLAB across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Excellent EPS Growth (29.63% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (29.75% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (4.96%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (8.16%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 54.11x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-117.65%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Interest Coverage (1.91x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 0.24%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Zim Laboratories Ltd Financial Statements
Comprehensive financial data for Zim Laboratories Ltd including income statement, balance sheet and cash flow
About ZIMLAB (Zim Laboratories Ltd)
Zim Laboratories Ltd (ZIMLAB) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹356.59 (Cr). Zim Laboratories Ltd has delivered a Return on Equity (ROE) of 4.96% and a ROCE of 8.16%. The debt-to-equity ratio stands at 0.48, reflecting the company's capital structure. Investors tracking ZIMLAB share price can monitor key metrics including P/E ratio, promoter holding of 33.26%, and quarterly earnings growth.
Company Details
Key Leadership
ZIMLAB Share Price: Frequently Asked Questions
What is the current share price of Zim Laboratories Ltd (ZIMLAB)?
As of 20 Feb 2026, 06:31 am IST, Zim Laboratories Ltd share price is ₹71.16. The ZIMLAB stock has a market capitalisation of ₹356.59 (Cr) on NSE/BSE.
Is ZIMLAB share price Overvalued or Undervalued?
ZIMLAB share price is currently trading at a P/E ratio of 54.11x, compared to the industry average of 31.77x. Based on this relative valuation, the Zim Laboratories Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of ZIMLAB share price?
The 52-week high of ZIMLAB share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Zim Laboratories Ltd share price?
Key factors influencing ZIMLAB share price include quarterly earnings growth (Sales Growth: -3.72%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Zim Laboratories Ltd a good stock for long-term investment?
Zim Laboratories Ltd shows a 5-year Profit Growth of 29.75% and an ROE of 4.96%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.48 before investing in ZIMLAB shares.
How does Zim Laboratories Ltd compare with its industry peers?
Zim Laboratories Ltd competes with major peers in the Pharmaceuticals. Investors should compare ZIMLAB share price P/E of 54.11x and ROE of 4.96% against the industry averages to determine competitive standing.
What is the P/E ratio of ZIMLAB and what does it mean?
ZIMLAB share price has a P/E ratio of 54.11x compared to the industry average of 31.77x. Investors pay ₹54 for every ₹1 of annual earnings.
How is ZIMLAB performing according to Bull Run's analysis?
ZIMLAB has a Bull Run fundamental score of 25.9/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does ZIMLAB belong to?
ZIMLAB operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Zim Laboratories Ltd share price.
What is Return on Equity (ROE) and why is it important for ZIMLAB?
ZIMLAB has an ROE of 4.96%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Zim Laboratories Ltd generates profits from shareholders capital.
How is ZIMLAB debt-to-equity ratio and what does it indicate?
ZIMLAB has a debt-to-equity ratio of 0.48, which indicates moderate leverage that should be monitored.
What is ZIMLAB dividend yield and is it a good dividend stock?
ZIMLAB offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Zim Laboratories Ltd shares.
How has ZIMLAB share price grown over the past 5 years?
ZIMLAB has achieved 5-year growth rates of: Sales Growth 6.42%, Profit Growth 29.75%, and EPS Growth 29.63%.
What is the promoter holding in ZIMLAB and why does it matter?
Promoters hold 33.26% of ZIMLAB shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Zim Laboratories Ltd.
What is ZIMLAB market capitalisation category?
ZIMLAB has a market capitalisation of ₹357 crores, placing it in the Small-cap category.
How volatile is ZIMLAB stock?
ZIMLAB has a beta of N/A. A beta > 1 suggests the Zim Laboratories Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is ZIMLAB operating profit margin trend?
ZIMLAB has a 5-year average Operating Profit Margin (OPM) of 12.20%, indicating the company's operational efficiency.
How is ZIMLAB quarterly performance?
Recent quarterly performance shows Zim Laboratories Ltd YoY Sales Growth of -3.72% and YoY Profit Growth of -117.65%.
What is the institutional holding pattern in ZIMLAB?
ZIMLAB has FII holding of 0.00% and DII holding of 0.24%. Significant institutional holding often suggests professional confidence in the Zim Laboratories Ltd stock.